This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Dezapelisib
- DrugBank Accession Number
- DB16137
- Background
Dezapelisib is under investigation in clinical trial NCT02456675 (INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/refractory Hodgkin Lymphoma).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Dezapelisib (DB16137)
- Weight
- Average: 421.45
Monoisotopic: 421.1121075 - Chemical Formula
- C20H16FN7OS
- Synonyms
- 6-(3-fluorophenyl)-3-methyl-7-[(1S)-1-(7H-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one
- Dezapelisib
- External IDs
- INCB-040093
- INCB040093
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 2K59L7G59M
- CAS number
- 1262440-25-4
- InChI Key
- RSIWALKZYXPAGW-NSHDSACASA-N
- InChI
- InChI=1S/C20H16FN7OS/c1-10-7-30-20-27-15(11(2)26-18-16-17(23-8-22-16)24-9-25-18)14(19(29)28(10)20)12-4-3-5-13(21)6-12/h3-9,11H,1-2H3,(H2,22,23,24,25,26)/t11-/m0/s1
- IUPAC Name
- 6-(3-fluorophenyl)-3-methyl-7-[(1S)-1-[(9H-purin-6-yl)amino]ethyl]-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one
- SMILES
- C[C@H](NC1=C2N=CNC2=NC=N1)C1=C(C(=O)N2C(C)=CSC2=N1)C1=CC=CC(F)=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 28651137
- BindingDB
- 50004547
- ChEMBL
- CHEMBL2216863
- ZINC
- ZINC000095564453
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Terminated Treatment Recurrent Adult Hodgkin's Lymphoma / Refractory Hodgkin Lymphoma 1 1 Active Not Recruiting Treatment B-cell Malignancy 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.031 mg/mL ALOGPS logP 2.64 ALOGPS logP 2.76 Chemaxon logS -4.1 ALOGPS pKa (Strongest Acidic) 9.75 Chemaxon pKa (Strongest Basic) 3.2 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 99.16 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 115.92 m3·mol-1 Chemaxon Polarizability 41.33 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at December 15, 2020 18:13 / Updated at July 18, 2023 22:58